XTX Topco Ltd Purchases 27,893 Shares of Dynavax Technologies Corporation (NASDAQ:DVAX)

Key Points

• XTX Topco Ltd increased its stake in Dynavax Technologies Corporation by 57.0% to approximately $997,000 in the first quarter.
• Deerfield Management Company L.P. Series C significantly raised its position in Dynavax by 23,990.1%, now owning shares valued at $66,325,000.
• Analysts have recently adjusted their target prices for Dynavax, with JMP Securities reducing it from $33.00 to $31.00 while maintaining a "market outperform" rating.

XTX Topco Ltd raised its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 57.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 76,854 shares of the biopharmaceutical company's stock after acquiring an additional 27,893 shares during the quarter. XTX Topco Ltd owned approximately 0.06% of Dynavax Technologies worth $997,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DVAX. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Dynavax Technologies in the 1st quarter valued at $312,000. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of Dynavax Technologies by 97.6% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock valued at $3,964,000 after purchasing an additional 153,302 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at $847,000. Finally, Deep Track Capital LP boosted its stake in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after acquiring an additional 5,265,000 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 0.1%

DVAX traded up $0.01 during trading on Tuesday, hitting $11.15. 1,189,820 shares of the company's stock were exchanged, compared to its average volume of 2,104,042. The company has a quick ratio of 10.84, a current ratio of 11.93 and a debt-to-equity ratio of 0.49. The business's 50 day moving average is $10.38 and its two-hundred day moving average is $11.60. Dynavax Technologies Corporation has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The stock has a market cap of $1.34 billion, a P/E ratio of -21.44 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. As a group, equities analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. JMP Securities cut their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.